GlaxoSmithKline Pharmaceuticals Intrinsic Value
GlaxoSmithKline Pharmaceuticals (GLAXO) median intrinsic value is ₹918.48 from 9 valuation models (range ₹459–₹1443), vs current price ₹2296.20 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit GlaxoSmithKline Pharmaceutical share price today.
GLAXO Valuation Methods Summary — DCF, Graham Number & P/E
GlaxoSmithKline Pharmaceuticals intrinsic value across 9 models vs current price ₹2296.20 — upside/downside and value range per method. Also explore GLAXO price movement history to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1443.20 | ₹1154.56 - ₹1731.84 | -37.1% | EPS: ₹65.60, Sector P/E: 22x |
| Book Value Method | asset | ₹459.24 | ₹413.32 - ₹505.16 | -80.0% | Book Value/Share: ₹134.14, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹688.86 | ₹619.97 - ₹757.75 | -70.0% | Revenue/Share: ₹244.02, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹918.48 | ₹826.63 - ₹1010.33 | -60.0% | EBITDA: ₹1548.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1036.83 | ₹829.46 - ₹1244.20 | -54.8% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹688.86 | ₹619.97 - ₹757.75 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1013.52 | ₹912.17 - ₹1114.87 | -55.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1148.10 | ₹1033.29 - ₹1262.91 | -50.0% | ROE: 49.1%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹688.86 | ₹619.97 - ₹757.75 | -70.0% | EPS: ₹65.60, BVPS: ₹134.14 |
GLAXO Intrinsic Value vs Market Price — All Valuation Models
GlaxoSmithKline Pharmaceuticals fair value range ₹459–₹1443 vs current market price ₹2296.20 across 9 valuation models. Browse GlaxoSmithKline Pharmaceutical financial data for revenue, profit, balance sheet and cash flow data.
GLAXO Intrinsic Value Analysis — Undervalued or Overvalued?
GlaxoSmithKline Pharmaceuticals median intrinsic value ₹918.48, current price ₹2296.20 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of GLAXO?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of GlaxoSmithKline Pharmaceuticals (GLAXO) is ₹918.48 (median value). With the current market price of ₹2296.20, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹459.24 to ₹1443.20, indicating ₹459.24 - ₹1443.20.
Is GLAXO undervalued or overvalued?
Based on our multi-method analysis, GlaxoSmithKline Pharmaceuticals (GLAXO) appears to be trading above calculated value by approximately 60.0%.
GLAXO Financial Health — Key Ratios vs Industry Benchmarks
GlaxoSmithKline Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.02 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 49.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 35.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.95x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GLAXO Cash Flow Quality — Operating & Free Cash Flow
GlaxoSmithKline Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,290 Cr | ₹1,267 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹582 Cr | ₹582 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹484 Cr | ₹484 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹811 Cr | ₹608 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹578 Cr | ₹578 Cr | Positive Free Cash Flow | 8/10 |